Form 4: Glaukos Corp CEO Thomas Burns Reports Acquisition of Shares and Stock Options

Thomas Burns, Chairman and CEO of Glaukos Corporation, reports the acquisition of common stock and stock options related to performance-based vesting and a bonus election.

Summary

• Thomas William Burns, Chairman and CEO of Glaukos Corporation, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 2,084 shares of common stock on March 14, 2024, related to the vesting of restricted stock units granted on March 24, 2022, based on the achievement of operational targets.
• An additional 15,418 shares of common stock were acquired on the same date, linked to restricted stock units granted on March 18, 2021, also based on achieving operational targets.
• Burns also acquired 21,275 restricted stock units that vest over a four-year period.
• He acquired stock options to purchase 4,208 shares of common stock, vesting based on the achievement of operational targets, with an exercise price of $55.18.
• Additionally, Burns acquired options to purchase 56,404 shares of common stock with an exercise price of $49.51, related to his 2023 bonus election.
• He also acquired options to purchase 36,891 shares of common stock with an exercise price of $85.78, vesting over four years.
• Burns directly owns 94,215 shares and indirectly owns 893,932 shares through the Burns Family Trust, 238,107 through the Burns Annuity Trust, 120,000 through the Burns Charitable Remainder Trust, 100,000 through the Thomas W. Burns Irrevocable Trust, and 100,000 through the Janet M. Burns Irrevocable Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of shares and options suggests the company is meeting its operational targets, which is a positive sign. The CEO's participation in the bonus election program also indicates confidence in the company's future.

Positives

• The vesting of restricted stock units and stock options indicates that Glaukos Corporation has achieved certain operational targets, which could be viewed positively by investors.
• The CEO's decision to receive his annual bonus in the form of stock options demonstrates confidence in the company's future performance.
• The increase in the CEO's holdings of company stock aligns his interests with those of shareholders.

Risks

• The vesting of shares and options is contingent on continued employment and the achievement of future operational targets, which may not be guaranteed.
• The value of the acquired shares and options is subject to market fluctuations and the company's performance.

Future Outlook

50% of the shares of common stock reported herein will vest and be delivered in March 2024, and the remaining 50% will vest and be delivered in December 2024.

Industry Context

Executive compensation through stock options and restricted stock units is a common practice in the pharmaceutical and medical device industries to align management's interests with those of shareholders and incentivize performance.

Comparison to Industry Standards

• Stock option grants and restricted stock units are standard components of executive compensation packages in the medical device industry.
• Companies like Alcon, Johnson & Johnson (Ethicon), and Bausch + Lomb also utilize similar equity-based compensation strategies to incentivize their executives.
• The vesting schedules and performance-based criteria outlined in the document are consistent with industry norms for long-term incentive plans.

Stakeholder Impact

• Shareholders may view the vesting of shares and options positively, as it indicates the company is achieving its operational targets.
• Employees may be motivated by the company's performance and the potential for future vesting of equity awards.

Key Dates